Fluticasone Furoate, Vilanterol and Lung Function Decline in Patients with Moderate COPD and Heightened Cardiovascular Risk.
about
Defining the relationship between COPD and CVD: what are the implications for clinical practice?At the Root: Defining and Halting Progression of Early Chronic Obstructive Pulmonary Disease.Single-inhaler triple therapy utilizing the once-daily combination of fluticasone furoate, umeclidinium and vilanterol in the management of COPD: the current evidence base and future prospects.What have we learned from observational studies and clinical trials of mild to moderate COPD?
P2860
Fluticasone Furoate, Vilanterol and Lung Function Decline in Patients with Moderate COPD and Heightened Cardiovascular Risk.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Fluticasone Furoate, Vilantero ...... eightened Cardiovascular Risk.
@en
type
label
Fluticasone Furoate, Vilantero ...... eightened Cardiovascular Risk.
@en
prefLabel
Fluticasone Furoate, Vilantero ...... eightened Cardiovascular Risk.
@en
P2093
P2860
P50
P1476
Fluticasone Furoate, Vilantero ...... Heightened Cardiovascular Risk
@en
P2093
Bartolomé R Celli
Courtney Crim
David E Newby
Fernando J Martinez
Julie A Anderson
Julie Yates
Natacha Gallot
Peter M A Calverley
SUMMIT (Study to Understand Mortality and Morbidity) Investigators
Sally Kilbride
P2860
P356
10.1164/RCCM.201610-2086OC
P407
P577
2018-01-01T00:00:00Z